Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 159,228

Document Document Title
WO/2018/185290A1
The invention provides agents for use in methods of saturation transfer mediated imaging (such as CEST imaging) in a subject, which agents comprise a liposome encapsulating a suitable sugar compound. The disclosure provides novel liposom...  
WO/2018/187551A1
Disclosed is a salt prepared from the STAT3 inhibitor known as 2-hydroxy-4-[[2-[[(4-methylphenyl)sulfonyl]oxy]acetyl]amino] benzoic acid and 2-amino-2-(hydroxymethyl)-1,3-propanediol. The salt is soluble in water and stable for extended...  
WO/2018/187484A1
Provided herein are, inter alia, methods of treating a cancer tumor in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of an adenosine A2A receptor antagonist, wherein the ...  
WO/2018/187642A1
Provided are antibody drug conjugates that bind PRLR, in particular human PRLR, their methods of making, and uses thereof.  
WO/2018/186421A1
The present invention addresses the problem of providing a cell population which includes mesenchymal cells showing low cell aggregation and is useful for the intravenous administration of a cell preparation, a production method therefor...  
WO/2018/184558A1
The present invention provides a humanized anti-TPBG antibody, a preparation method therefor, a conjugate thereof, and applications. The humanized anti-TPBG antibody comprises: (a), a framework region comprising a residue of a human anti...  
WO/2018/187414A1
The present disclosure provides compounds and methods for inhibiting mTORC2, as well as methods for treating cancers such as glioblastoma.  
WO/2018/185135A1
The invention describes anti-cancer therapies comprising using an MDM2 inhibitor in combination with a PD-1 antagonist and a LAG-3 antagonist, each as described herein.  
WO/2018/187518A1
The present invention provides antibodies and antigen-binding fragments thereof that bind to ILT4 (immunoglobulin-like transcript 4) and combinations thereof, e.g., with an anti-PD1 antibody. Also provided are methods of use thereof, for...  
WO/2018/184585A1
The present invention provides a compound for inhibiting IDO, a manufacturing method and a use thereof. The compound has a general structural formula of (I), wherein (II) is selected from a cis-isomer, a trans-isomer, or a mixture of cis...  
WO/2018/187228A1
Biomarkers to screen for, identify, and/or characterize lung cancer in a subject are disclosed. Also disclosed herein are methods for distinguishing lung cancer from another disease. Also disclosed herein are methods for detecting metast...  
WO/2018/187786A1
The present invention relates to a unipotent neutrophil progenitor population, to methods of preparing and using same. In certain embodiments, the neutrophil progenitor population have at least the phenotype CD45+, CD41-, CD127 (IL-7Rα)...  
WO/2018/186775A1
The invention relates to 4-((2-(6-(4-methylpiperazine- 1-carbonyl)naphthalen-2-yl)ethyl)amino)quinazoline-6-carboni trile salts which exhibit the properties of an inhibitor of cyclin-dependent kinase CDK8/CDK19. The invention also relate...  
WO/2018/187288A1
The present invention relates to compounds and methods for inhibiting CDK5 or the CDK5 pathway for treating long QT syndrome (LQTS), and in particular Timothy Syndrome (TS). Additionally, the invention relates to small molecule and gene ...  
WO/2018/187636A1
This disclosure provides cell surface anchoring antigen conjugates, formulations comprising cell surface anchoring antigen conjugates, and methods of using the same for treating cancer.  
WO/2018/184074A1
The invention relates to a method for treating a side effect of chimeric antigen receptor (CAR) T cell therapy, the method comprising administering a mesenchymal stem cell (MSC) to a subject who has been or is being administered CAR T ce...  
WO/2018/184561A1
Disclosed in the present invention are compounds having an aldolase selective inhibiting activity, a preparation method therefor, a pharmaceutical composition comprising the compounds, and uses of the compounds in preparation of drugs fo...  
WO/2018/187643A1
The present disclosure is directed to a crystalline, hydrated form of afatinib dimaleate having about 2 to 3 molecules of water, designated as Form Z, a pharmaceutical composition comprising the form, its method of use for treating a pat...  
WO/2018/187287A1
A porous protocell is provided comprising one or more non-integrating vectors comprising nucleic acid encoding a non-nucleolytic fusion protein comprising a protein sequence that specifically binds a sequence in a double strand nucleic a...  
WO/2018/185266A1
The invention relates to compounds of formula: wherein R1 to R7 are as defined in the description. These compounds are useful as inhibitors of the YAP/TAZ-TEAD interaction.  
WO/2018/185618A1
The present invention relates to anti-CDH6 ADCs in combination with an anti-GITR antibody, and their uses for the treatment of cancer.  
WO/2018/185495A1
The invention relates to novel compounds with the ability to link an immune response to a defined therapeutic target, to the use of said compounds in treating cancer and infectious diseases, to compositions containing said compounds, pro...  
WO/2018/185494A1
The invention relates to novel compounds with the ability to link an immune response to a defined therapeutic target, to the use of said compounds in treating cancer and infectious diseases, to compositions containing said compounds, pro...  
WO/2018/187652A1
The present invention relates to 2,4-diaminopyrimidines of formula (I) and pharmaceutically acceptable salts thereof, purification methods for the same, pharmaceutical compositions containing them, methods of obtaining and using them for...  
WO/2018/184587A1
The present invention provides a use of carrimycin and a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment and/or prevention of tumors. The carrimycin and the pharmaceutically acceptable salt ...  
WO/2018/186366A1
The present invention addresses the problem of providing a novel cyclin-dependent kinase 8 and/or 19 inhibitor that is useful as an anticancer agent. The present invention relates to a cyclin-dependent kinase 8 and/or 19 inhibitor that c...  
WO/2018/184107A1
Novel activators of the APC complex and methods and uses of these activators are provided. In particular, the activators are used for increasing resistance to stress and/or increasing lifespan in a plant or mammalian cell, in a plant or ...  
WO/2018/187227A1
Disclosed are methods and kits for treating patients, particularly cancer patients, using bavituximab in combination therapies with immuno-oncology (IO) agents such as checkpoint inhibitor antibodies. The methods and kits are based on th...  
WO/2018/187357A1
The present invention provides, in part, compositions comprising an inhibitor of cyclin-dependent kinase 7 (CDK7) and sulfobutyl ether-P-cyclodextrin. Also provided are methods of using a disclosed composition for treating proliferative ...  
WO/2018/187331A1
The present invention provides novel Compound (1) having tumor vascular remodeling effect and/or anti-CAF (Cancer Associated Fibroblasts) activity, or a pharmaceutically acceptable salt thereof, optionally in a pharmaceutically acceptabl...  
WO/2018/187191A1
Methods of treating cancer with particular doses of anti-ICOS antibodies are provided.  
WO/2018/186418A1
The present invention addresses the problem of providing a cell population which includes attached cells derived from fetal appendages and has a low differentiation potential, a production method therefor, and a pharmaceutical compositio...  
WO/2018/184113A1
There is described herein imidopiperidine compounds as inhibitors of human polynucleotide kinase phosphatase.  
WO/2018/184484A1
Provided is a cytokine combination for treating a tumor and/or preventing recurrence or metastasis of the tumor. The cytokine combination comprises at least 3 cytokines. The cytokines are selected from the following groups: an IL12 or a ...  
WO/2018/184448A1
Provided is a recombinant Ganoderma lucidum immunoregulatory protein mutant having an anti-tumor effect.  
WO/2018/184206A1
Disclosed methods of making certain pyrrolopyrimidine derivatives, which are useful in the treatment of proliferation disorders and other diseases related to the dysregulation of kinase (such as, but not limited to, EGFR(including HER), ...  
WO/2018/186770A1
The invention relates to the chemical and pharmaceutical industry. Proposed is a use of synthetic peptides as specific clathrin inhibitors. Also proposed is a method for preventing or treating a disease or condition in an animal, compris...  
WO/2018/185232A1
This disclosure relates to combination therapies targeting two or all of PD-1, TIM-3, and LAG-3 using antibodies specific for these targets in patients who are in need of enhanced immunity. Also included in the disclosure are composition...  
WO/2018/187411A1
Described herein are methods, compositions, and kits for treating and/or preventing in a subject one or more side effects associated with radiation and/or chemotherapy exposure, including methods, compositions and kits that include an ac...  
WO/2018/184678A1
The invention relates to methods, composition and uses for the of treatment of cancer selected from the group consisting of HCC, RCC, NSCLC, ovarian cancer, CCA, PTC and FTC in a subject, which comprise administering an HDAC inhibitor in...  
WO/2018/184604A1
The present invention provides 1-acyl-lysophosphatidyl derivatives of general formula I, (I) wherein R is C4 to C30 alifatic hydrocarbyl chain, R1 is selected from H or C1 to C10 alkyl, preferably C1 to C6 alkyl, R2 is selected from H, C...  
WO/2018/186032A1
The present invention provides an anticancer agent based on a novel mechanism. Specifically, the present invention relates to an inhibitor that inhibits gene expression regulation by SWI/SNF complex-dependent NF-κB or corepressor comple...  
WO/2018/183420A1
Provided herein are methods and compositions for treating cancer, including cancer that is not responsive to immunotherapy. In one aspect, the methods of treatment comprise administering to the subject a therapeutically effective amount ...  
WO/2018/182776A1
Methods are provided for treating cancers using a conjugate herein described as Conjugate 5, or a pharmaceutically acceptable salt thereof. Methods for treating cancers using Conjugate 5, or a pharmaceutically acceptable salt thereof, to...  
WO/2018/177865A1
The present invention relates to the use of compounds having an anti- heparanase activity of formu la [R - L1- Ar1- L - Ar]2- X, wherein X is selected from the group consisting of SO2, C1 -C4 a lkylene, linear or branched, and wherein Ζ...  
WO/2018/179302A1
The present invention provides a cancer cell-specific anti-podoplanin antibody or an antigen-binding fragment thereof. The anti-podoplanin antibody is against the amino acid sequence of human podoplanin represented by SEQ ID NO: 1, the s...  
WO/2018/178378A1
The present invention relates to new CD22 Chimeric Antigen Receptors (CD22 CAR), an engineered immune cell endowed with said new CD22 CAR and comprising at least inactivated TRAC gene for use in therapy. The engineered immune cells endow...  
WO/2018/183418A1
Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula (I), or a ste...  
WO/2018/183908A1
Described herein are compositions and methods of using single-cell RNA-sequencing to identify treatment resistance in patients with ovarian cancer. Also, described herein are compositions and methods for treatment targeting resistance in...  
WO/2018/184019A1
The present invention presents 2-(acylamino)imidazoles with therapeutic activity, including selective activity against cancer cells, and compositions comprising them. Methods of using and preparing the 2-(acylamino)imidazoles are also pr...  

Matches 1 - 50 out of 159,228